Lagast H, Pascual-Lopez A, Dejace P, Klastersky J
Eur J Clin Microbiol. 1986 Feb;5(1):98-102. doi: 10.1007/BF02013477.
To determine whether high doses of amikacin would prevent the development of resistance in clinical isolates, the serum bactericidal activity and killing rate of conventional and high doses of amikacin and piperacillin alone and in combination were measured in volunteer sera against a series of ten strains each of Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. Amikacin serum levels were 24.9 +/- 6.0 mg/l 1 h after infusion of the 7.5 mg/kg dose and 44.8 +/- 5.0 mg/l after the two-fold dose. Median serum bactericidal titers for low dose piperacillin + amikacin were 1:8-1:64 and for high-dose piperacillin + amikacin 1:16-1:128. Both were satisfactory, except against piperacillin-resistant Pseudomonas aeruginosa (median bactericidal titers less than or equal to 1:2), and both combinations had equivalent killing rates.
为了确定高剂量阿米卡星是否能预防临床分离株产生耐药性,在志愿者血清中测定了常规剂量和高剂量的阿米卡星及哌拉西林单独使用和联合使用时针对一系列10株大肠杆菌、肺炎克雷伯菌和铜绿假单胞菌的血清杀菌活性和杀菌率。输注7.5mg/kg剂量后1小时,阿米卡星血清水平为24.9±6.0mg/L,双倍剂量后为44.8±5.0mg/L。低剂量哌拉西林+阿米卡星的血清杀菌滴度中位数为1:8 - 1:64,高剂量哌拉西林+阿米卡星的血清杀菌滴度中位数为1:16 - 1:128。除了对哌拉西林耐药的铜绿假单胞菌(杀菌滴度中位数小于或等于1:2)外,两者均令人满意,且两种联合用药的杀菌率相当。